Illumina

Illumina is Committed to Bringing Lifesaving GRAIL Test to People Globally as European Review Process Enters Second Phase

Thursday, July 22, 2021 - 5:49pm

We look forward to presenting our position during the Phase II process, said Charles Dadswell, General Counsel for Illumina.

Key Points: 
  • We look forward to presenting our position during the Phase II process, said Charles Dadswell, General Counsel for Illumina.
  • Illumina is also challenging the ECs jurisdiction to investigate the transaction under Article 22 of the European Union (EU) Merger Regulation.
  • Illumina has filed an action in the General Court of the EU seeking annulment of the ECs jurisdiction to review the acquisition.
  • Illuminas re-acquisition of GRAIL means that millions of citizens across the European Economic Area (EEA) will be able to access life-saving early cancer screening years sooner.

LetsGetChecked to Provide Next-Generation Sequencing on Positive COVID-19 Tests To Determine Virus Variants

Tuesday, June 22, 2021 - 11:00am

LetsGetChecked will utilize its CAP-Accredited, CLIA Certified laboratory in Monrovia, California and the Illumina NovaSeq 6000 System, a powerful Next-Generation Sequencing (NGS) platform, enabling the detection of SARS-CoV-2 and identification of different variants of the virus.

Key Points: 
  • LetsGetChecked will utilize its CAP-Accredited, CLIA Certified laboratory in Monrovia, California and the Illumina NovaSeq 6000 System, a powerful Next-Generation Sequencing (NGS) platform, enabling the detection of SARS-CoV-2 and identification of different variants of the virus.
  • Additionally, LetsGetChecked will sequence positive samples provided by COVIDNet from across the state of California.
  • We are excited to add sequencing capabilities to our fully integrated end-to-end model to support public health initiatives in the United States.
  • We congratulate LetsGetChecked on their expansion into sequencing to help the country stay ahead of emergence and spread of harmful variants, said Phil Febbo, MD, Chief Medical Officer of Illumina.

Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic

Thursday, April 22, 2021 - 9:05pm

b'Illumina, Inc. (NASDAQ: ILMN) and Kartos Therapeutics, Inc. are pleased to announce a new partnership to co-develop a TP53 companion diagnostic (CDx) based on the content of Illumina\xe2\x80\x99s comprehensive genomic profiling assay, TruSight\xe2\x84\xa2 Oncology 500 (TSO 500).

Key Points: 
  • b'Illumina, Inc. (NASDAQ: ILMN) and Kartos Therapeutics, Inc. are pleased to announce a new partnership to co-develop a TP53 companion diagnostic (CDx) based on the content of Illumina\xe2\x80\x99s comprehensive genomic profiling assay, TruSight\xe2\x84\xa2 Oncology 500 (TSO 500).
  • This companion diagnostic for multiple hematologic indications will be the first to use TSO 500 with peripheral whole blood as a diagnostic sample type.\n\xe2\x80\x9cWith this partnership, Illumina will expand the TruSight Oncology offerings into hematologic malignancies,\xe2\x80\x9d said Phil Febbo, MD, Chief Medical Officer of Illumina.
  • Based on the content of TSO 500, Illumina will be adding an in vitro diagnostic (IVD) test to the TruSight Oncology product family.
  • Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Illumina Named One of Singapore’s Best Employers

Tuesday, April 13, 2021 - 4:38am

b'Illumina, Inc., today announced, for the second consecutive year, Illumina is honored as one of Singapore\xe2\x80\x99s Best Employers in a survey sponsored by The Straits Times and the marketing firm Statista .

Key Points: 
  • b'Illumina, Inc., today announced, for the second consecutive year, Illumina is honored as one of Singapore\xe2\x80\x99s Best Employers in a survey sponsored by The Straits Times and the marketing firm Statista .
  • Illumina was second in Health Care and Equipment Services and placed 30th on the overall list.
  • Today, Illumina Singapore has increased the number of employees to more than 1,300 and grown to three buildings, occupying ten times the original space\xe2\x80\x94now totaling 385,000 square feet.
  • To learn more, visit www.illumina.com and connect with us on Twitter , Facebook , LinkedIn , Instagram , and YouTube .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210412006017/en/\n'

Illumina Committed to Pursuing GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test

Tuesday, March 30, 2021 - 8:17pm

Illumina will pursue its right to proceed with the transaction, the impact of which would accelerate the adoption of a breakthrough multi-cancer early detection blood test.

Key Points: 
  • Illumina will pursue its right to proceed with the transaction, the impact of which would accelerate the adoption of a breakthrough multi-cancer early detection blood test.
  • Improving early cancer detection is the most promising approach to bending the cancer mortality curve, said Francis deSouza, Chief Executive Officer of Illumina.
  • Illumina strongly believes that acquiring GRAIL is in the best interest of patients, is procompetitive, and benefits the multi-cancer early detection field as a whole.
  • Illumina intends to pursue all legal options in order to complete the acquisition and deliver the strategic benefits to its stakeholders.

Illumina Announces Board Changes

Thursday, March 18, 2021 - 8:05pm

Illumina, Inc. (NASDAQ: ILMN) (the Company) today announced that Jay Flatley has decided to step down from the Board of Directors and John W. Thompson will be appointed as the Companys new Chair of the Board.

Key Points: 
  • Illumina, Inc. (NASDAQ: ILMN) (the Company) today announced that Jay Flatley has decided to step down from the Board of Directors and John W. Thompson will be appointed as the Companys new Chair of the Board.
  • Illumina has significant opportunities ahead and I am confident that John, Francis and the entire Illumina leadership team will continue the Companys strong legacy of innovation and execution for long-term success.
  • Mr. Flatley led Illumina as CEO from 1999 until mid-2016, served as Executive Chair from mid-2016 through 2019, and currently serves as Chair of the Board.
  • Mr. Thompson is a member of the board of trustees for the Wetlands America Trust and was formerly a member of the national board of Teach for America.

US Court Grants MGI's Motion to Amend in Suit Against Illumina

Tuesday, February 23, 2021 - 2:07pm

During this patent prosecution process, MGI alleges that Illumina intentionally withheld or failed to disclose a reference to a paper by Terez Kovacs and Laslo Otvos ("Kovacs")[1].

Key Points: 
  • During this patent prosecution process, MGI alleges that Illumina intentionally withheld or failed to disclose a reference to a paper by Terez Kovacs and Laslo Otvos ("Kovacs")[1].
  • Accordingly, MGI's motion for leave to amend is granted.
  • MGI has already initiated an antitrust violation complaint towards Illumina in the United States in Jan 2021.
  • Providing real-time, comprehensive, life-long solutions, its mission is to develop and promote advanced life science tools for future healthcare.

Illumina to Webcast Upcoming Investor Conference Presentations

Tuesday, December 22, 2020 - 12:00pm

Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.

Key Points: 
  • Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.
  • J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021
    The live webcasts can be accessed under the Investor Info section of the "company" tab at www.illumina.com .
  • Replays will be posted on Illuminas website as soon as possible after the event and will be available for at least 30 days following.
  • Illumina is improving human health by unlocking the power of the genome.

Slone Partners Places John Leite as Chief Business Officer at InterVenn Biosciences

Thursday, December 3, 2020 - 9:00am

SOUTH RIDING, Va., Dec. 3, 2020 /PRNewswire-PRWeb/ -- Slone Partners , a nationwide executive search firm for life science, biotechnology, and diagnostics companies, has announced the placement of John Leite as Chief Business Officer at InterVenn Biosciences .

Key Points: 
  • SOUTH RIDING, Va., Dec. 3, 2020 /PRNewswire-PRWeb/ -- Slone Partners , a nationwide executive search firm for life science, biotechnology, and diagnostics companies, has announced the placement of John Leite as Chief Business Officer at InterVenn Biosciences .
  • In his new role, Leite will direct all business operations for the company as part of its global leadership team.
  • Over the past six years, Leite served as Vice President of Oncology, Market Development & Product Marketing for the oncology business unit at Illumina .
  • "We are thrilled to bring John on board at a very exciting time for our company," said Aldo Carrascoso , Chief Executive Officer at InterVenn.

Illumina to Webcast Upcoming Investor Conference Presentation

Wednesday, November 18, 2020 - 12:00pm

Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.

Key Points: 
  • Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.
  • The live webcast can be accessed in the Investor Info section of Illumina's web site under the "company" tab at www.illumina.com .
  • A replay of the presentation will be posted on Illuminas website as soon as possible after the event and will be available for at least 30 days following.
  • Illumina is improving human health by unlocking the power of the genome.